UBS Group
TLSI icon

UBS Group’s TriSalus Life Sciences TLSI Stock Holding History

UBS Group’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
223,047
+143,495
+180% +$570K ﹤0.01% 5718
2026
Q1 		$318K Buy
79,552
+74,403
+1,445% +$364K ﹤0.01% 6369
2025
Q4 		$35.9K Sell
5,149
-3,829
-43% -$21.4K ﹤0.01% 7408
2025
Q3 		$41.7K Sell
8,978
-7,714
-46% -$36.1K ﹤0.01% 7693
2025
Q2 		$91K Buy
16,692
+9,883
+145% +$53K ﹤0.01% 7318
2025
Q1 		$37.6K Buy
6,809
+6,787
+30,850% +$36.1K ﹤0.01% 7790
2024
Q4 		$110 Hold
22
– – ﹤0.01% 9639
2024
Q3 		$101 Sell
22
-1,966
-99% -$10.4K ﹤0.01% 9159
2024
Q2 		$11K Buy
1,988
+1,597
+408% +$13.5K ﹤0.01% 7667
2024
Q1 		$3.81K Sell
391
-16,424
-98% -$152K ﹤0.01% 7695
2023
Q4 		$142K Sell
16,815
-8,117
-33% -$41.8K ﹤0.01% 5983
2023
Q3 		$128K Buy
24,932
+24,910
+113,227% +$204K ﹤0.01% 5673
2023
Q2 		$231 Sell
22
-90
-80% -$936 ﹤0.01% 8362
2023
Q1 		$1.15K Sell
112
-1,947
-95% -$19.7K ﹤0.01% 8798
2022
Q4 		$20.7K Buy
2,059
+2,037
+9,259% +$20.4K ﹤0.01% 7619
2022
Q3 		$0 Sell
22
-24,795
-100% -$245K ﹤0.01% 10924
2022
Q2 		$244K Buy
24,817
+24,694
+20,076% +$243K ﹤0.01% 4763
2022
Q1 		$1K Sell
123
-1,329
-92% -$13.1K ﹤0.01% 9930
2021
Q4 		$14K Buy
1,452
+1,446
+24,100% +$14.4K ﹤0.01% 8355
2021
Q3 		$0 Sell
6
-1,143
-99% -$11.2K ﹤0.01% 10084
2021
Q2 		$11K Buy
1,149
+1,132
+6,659% +$11.1K ﹤0.01% 7979
2021
Q1 		$0 Buy
+17
New +$172 ﹤0.01% 9465

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

UBS Group's TLSI Position: Q2 2026 in Review

UBS Group increased its TriSalus Life Sciences (TLSI) stake by 180% in Q2 2026, buying an estimated $570K and bringing the position to 223,047 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #5718.

UBS Group first reported a position in TLSI in Q1 2021 and has held it in 22 quarters since. 79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • UBS Group held 223,047 shares of TriSalus Life Sciences worth $1.01M as of Q2 2026.
  • UBS Group bought 143,495 TriSalus Life Sciences shares in Q2 2026, an estimated $570K.
  • TriSalus Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5718 holding.
  • UBS Group first reported a position in TriSalus Life Sciences in Q1 2021 and has held it in 22 quarters since.
  • 79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.